We have studied the antiemetic effects of propofol when mixed with morphine in a patientcontrolled analgesia (PCA) pump after major gynaecological surgery. In a double-blind, randomized, controlled study, 50 women, ASA I or II, received a standardized anaesthetic comprising thiopental, morphine, atracurium, nitrous oxide and oxygen with enflurane, and received postoperative PCA with morphine mixed with either 1% propofol or Ivelip. The PCA bolus was morphine 1 mg with propofol 5 mg or Ivelip 0.5 ml, with a lockout time of 5 min. Postoperative nausea and vomiting (PONV) were assessed by the nursing staff using a four-point ordinal scale and by the patient using a visual analogue scale for 48 h after surgery. The two groups were similar in the potential factors influencing the incidence of PONV. There were no significant differences between the two groups in any of the study measurements of PONV. There were no side effects after propofol. Propofol, when mixed with morphine in this dose combination for PCA, did not decrease the incidence of nausea and vomiting in women undergoing major gynaecological surgery. (Br. J. Anaesth. 1998; 80: 152-154) 
Postoperative nausea and vomiting (PONV) is one of the more common and distressing causes of morbidity after major surgery. There is a decreased incidence of PONV after propofol. [1] [2] [3] [4] Whether propofol has direct antiemetic properties or is merely less emetogenic than other anaesthetic drugs is not known. There has been interest in using subhypnotic doses of propofol both to treat and prevent nausea and vomiting after cancer chemotherapy and surgery. [5] [6] [7] [8] Small doses of propofol given in recovery were successful in treating PONV, 7 but the results with postoperative infusion for 24-48 h after surgery were conflicting. [8] [9] [10] [11] We have studied the effects of simultaneous administration of propofol and morphine patient-controlled analgesia (PCA) on the incidence of PONV.
Patients and methods
After obtaining approval from the local Ethics Committee, we studied ASA I or II women, aged 30-75 yr, undergoing elective hysterectomy (either abdominal or vaginal). We excluded women weighing more than 100 kg, those who were unable to use patient-controlled analgesia (PCA) and any patient who suffered from epilepsy, ear disease, liver disease, hyperlipidaemia or were receiving drugs with antiemetic properties.
After obtaining written informed consent, all patients were premedicated with temazepam 20-30 mg, 1 h before surgery. Anaesthesia was induced with thiopental, atracurium and morphine 0.2 mg kg
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, and maintained with enflurane (end-tidal 0.5-2%) and 60% nitrous oxide in oxygen. At the end of surgery residual neuromuscular block was antagonized with neostigmine 2.5 mg and glycopyrrolate 0.5 mg. After extubation of the trachea all patients were transferred to the recovery area where they received a PCA (Graseby 3300) consisting of morphine 100 mg mixed in 50 ml of either 1% propofol or 10% Ivelip (10% soya oil, 2.5% glycerol, Clintec).
Derriford Hospital Pharmacy prepared all the study solutions under aseptic conditions and randomized the patients. The stability of morphine, propofol and Ivelip mixtures have been verified previously by HPLC (Dr P. Adams, principal pharmacist, South West Pharmaceutical Quality Control Laboratory, Torbay Hospital, Torquay, personal communication). The patient, anaesthetist, investigators and all nurses were unaware of the contents of the syringe. Another two syringes, each containing 1 ml of either propofol or 10% Ivelip, were supplied by the pharmacy with the appropriate PCA syringe. The first 1-ml bolus was given i.v. by the recovery nurse if the patient complained of nausea or was vomiting. The second syringe was given 5 min later, followed by rescue antiemetic (prochlorperazine 12.5 mg i.m. every 6 h) after another 5 min, as required. The PCA pump was programmed to give morphine 1 mg with either propofol 5 mg or Ivelip 0.5 ml in each successful demand, with a lockout of 5 min. The maximum possible dose of propofol in 1 h was 60 mg. A separate i.v. cannula was used for the PCA. All patients were prescribed oxygen for 24 h and when comfortable were transferred to the ward. At 4-hourly intervals for the first 24 h, and 8-hourly intervals for the second 24 h, the ward nurses recorded PCA demands and doses, nausea scores, episodes of vomiting, antiemetics given and sedation scores.
PONV was recorded as: (1) no nausea or vomiting; (2) nausea alone; (3) nausea with vomiting on one or two occasions; and (4) nausea with vomiting more than twice. Sedation was recorded as: (1) awake; (2) dozing intermittently; (3) mostly sleeping; and (4) only awakens when aroused.
Mean nausea scores for each patient were obtained as the mean of the nursing PONV scores during each 24-h period. In addition, at 24 and 48 h, patients completed two 10-cm visual analogue scales (VAS) for pain and nausea, ranging from none to the worst possible. The amount of morphine and rescue antiemetics given by the nurses were also recorded.
The sample size was chosen to provide a 75% probability of demonstrating a reduction in the incidence of PONV from 60% to 30% when ␣:0.05. The data were analysed using the Student's t test, Mann-Whitney U test and Fisher's exact test, where appropriate (Instat v2.01, GraphPad; Macintosh System B-7.01), and the level of statistical significance was 5%.
Results
A total of 50 patients were entered into the study. One patient receiving Ivelip was excluded within the first 24 h because of excessive sedation; 25 patients received propofol and 24 received Ivelip. Patient characteristics, duration of anaesthesia and time spent in recovery were similar in both groups (table  1) .
The amount of morphine used from the PCA, visual analogue scores for pain and sedation scores were similar in both groups at 24 and 48 h (table 2) . There were no significant differences between the two groups in any of the measurements of PONV (table 3) .
Discussion
Postoperative nausea and vomiting (PONV) after anaesthesia is less likely with propofol than with other anaesthetic agents, and the magnitude of the reduction depends on the method of administration, time of measurement and baseline incidence of PONV. 4 PONV is least when propofol is used for maintenance and induction of anaesthesia. 4 The action of propofol on dopamine [12] [13] [14] and 5HT 3 receptors 15 has been investigated, and it seems unlikely that propofol has important activity at these receptors.
There has been interest in using propofol specifically as an antiemetic drug, both as treatment and for prophylaxis.
1 Propofol 10 mg given in recovery was effective in 69% of patients with established PONV (compared with 35% responding to placebo). 7 Schulman, Rockett and Canada reported that a patient with severe refractory PONV was treated successfully with a propofol infusion for 5 days. 16 Gan and colleagues have published their preliminary results using a target-controlled infusion of propofol to treat PONV in recovery. 17 Patients with PONV were given infusions of propofol in increasing doses until treatment was successful or the study limit (a target concentration of 800 ng ml 91 ) was reached. They found that a target concentration of 405 ng ml 91 reduced the verbal nausea score to less than 3 or by 50%. This blood concentration of propofol would normally be obtained with a bolus dose of 10 mg and an infusion of 1 mg kg 91 h
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. Details of the patients, anaesthetic techniques and whether a control group were used were not given. 17 Postoperative infusions of propofol have been tried as prophylaxis against PONV, with conflicting results. [8] [9] [10] [11] Patients in the study by Ewalenko and colleagues 8 received an infusion of propofol started in recovery after thyroid surgery. The incidence of PONV was reduced from 65% (in the control group) to 10%, 8 but patients in two other studies did not benefit from using propofol in this way. 9 10 In these three studies, [8] [9] [10] propofol was not used for anaesthesia, although Scudieri and colleagues 10 started the subhypnotic infusion of propofol before anaesthesia and surgery. Modest success has been reported in British Journal of Anaesthesia reducing the severity of PONV after intrathecal morphine using a postoperative infusion of propofol for 24 h.
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Our premise when starting this study was that by coupling the dose of propofol to that of morphine and by using boluses, which have been shown to be effective, propofol with morphine in a PCA may be an effective technique for both analgesia and antiemesis. In addition, continuous infusion of propofol requires an additional i.v. cannula and syringe driver, and we found this a practical disadvantage in our previous study. 9 The maximum dose of propofol that could be obtained from the PCA pump was 60 mg in 1 h; in practice, the mean propofol dose was much less than this, and the maximum dose of propofol received during any 4-h period by a patient in this study was 180 mg. This is considerably less than would be delivered using the 1-mg kg 91 h 91 scheme of previous studies of continuous postoperative infusions of propofol. 9 10 The dose of propofol obtained by the patients from the PCA in our study may have been too low if propofol does indeed have antiemetic properties. We chose a propofol bolus dose of 5 mg, which we thought would be safe for the patients to receive on the ward. If we had used a 10-mg bolus, and morphine consumption remained the same, the mean hourly propofol dose would have been 19.6 mg in the first 24 h. This is still less than 1 mg kg 91 h 91 used previously for prophylaxis of nausea and vomiting after surgery 9 10 or cancer chemotherapy. 5 6 However, the patient who used the most propofol in any 4-h period in this study would have received a mean of 90 mg per hour if a 10-mg propofol bolus had been chosen. She weighed 68 kg, so the dose would have been more than 1 mg kg 91 h 91 during this time; this may not be safe on a general ward.
In summary, we believe that it is unlikely that propofol will have important postoperative use in treating or avoiding PONV.
